Vertex Pharmaceuticals up after raising 2026 revenue forecast

By Reuters News

** Shares of Vertex Pharmaceuticals VRTX.O rise 2.1% to $565 in extended trading

** Co raises its annual revenue forecast to between $13.15 billion and $13.25 billion, from $13.1 billion to $13.2 billion previously

** Posts Q3 revenue of $3.44 billion compared with analysts' estimates of $3.42 billion, according to data compiled by LSEG

** Reports Q3 adj. profit per share of $4.76 versus average estimate of $4.79

** BMO says a clean quarter clears the path to the FDA's November 30 decision on Vertex's povetacicept for IgA nephropathy

** As of last close, stock up 22% YTD

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.